ChromaDex Corp. (CDXC) - יחס מחיר להכנסות חזויות

ChromaDex Corporation (CDXC) is a recognized authority in cellular rejuvenation due to its Niagen patents. The projected P/S metric helps assess the business valuation, with the indicator holding around 3.20. The company capitalizes on the demand for biohacking in the US and Asia by creating components for anti-aging cosmetics. Stable production line operations and planned capacity utilization guarantee uninterrupted product output.

The optimization of agricultural raw material supply chains and the diversification of extractors at ChromaDex Corporation (CDXC) directly impact the stability of future revenue streams. By analyzing the forward P/S valuation metric on GURU.Markets, an investor can see the ratio of current market capitalization to projected sales, enabling a real-time assessment of the company's market value against current management guidance and the determination of the premium paid for expected growth.